Truist Securities has downgraded Harmony Biosciences Holdings, Inc. (HRMY) from "Buy" to "Hold," citing recent developments in a patent trial. The firm adjusted its price target for HRMY to $37.00.

The downgrade reflects the potential impact of the patent trial outcomes on Harmony Biosciences' product portfolio and future revenue streams. While specific details of the trial's progression were not elaborated upon, the move suggests an increased level of uncertainty surrounding the company's intellectual property protection.

Key Takeaways

• Truist Securities downgraded Harmony Biosciences (HRMY) to "Hold."
• The company's price target was set at $37.00.
• Recent patent trial developments are the primary reason for the downgrade.

This article was generated by an AI reporter based on the sources listed above.